methylphenidate has been researched along with Critical Illness in 2 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Critical Illness: A disease or state in which death is possible or imminent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "refusal of food, apathy and congestive heart failure) resulted in recovery to a stable health condition and stabilization of dementia." | 1.46 | [Methylphenidate in a patient with Alzheimer's disease : Increase in drive and cardiac performance]. ( Schuhfried, G, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schuhfried, G | 2 |
| Wergin, R | 1 |
| Modrykamien, A | 1 |
1 review available for methylphenidate and Critical Illness
| Article | Year |
|---|---|
Cognitive impairment in ICU survivors: assessment and therapy.
Topics: Cholinesterase Inhibitors; Cognition; Cognition Disorders; Cognitive Behavioral Therapy; Critical Il | 2012 |
1 other study available for methylphenidate and Critical Illness
| Article | Year |
|---|---|
[Methylphenidate in a patient with Alzheimer's disease : Increase in drive and cardiac performance].
Topics: Aged, 80 and over; Alzheimer Disease; Central Nervous System Stimulants; Critical Illness; Fatigue; | 2017 |